AndhraNews.net
Home » Features » Health » Protein

Protein


About Protein

Protein in News

Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
Novartis International AG /Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial With Medusa(TM) Exenatide
Flamel Technologies (NASDAQ: FLML) today announced positive interim results from a Phase 1a clinical trial in healthy volunteers of a once weekly subcutaneous injection formulation of exenatide using its proprietary Medusa™ technology (FT228). The study achieved all safety and pharmacokinetic (PK) assessment objectives throughout ascending single dose administrations of FT228

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

Sobi receives orphan drug designation for Alprolix® in Switzerland
Swedish Orphan Biovitrum AB (publ) (Sobi) has received orphan drug designation in Switzerland for its extended half-life haemophilia drug candidate Alprolix® (rFIXFc) developed for the treatment of haemophilia B. An orphan drug designation is to encourage the development of medicines for rare diseases and provides orphan status to drugs and biologics under development.

Balancing Your Hectic Holiday Hunger Pangs
(Family Features) As the days get shorter and your holiday to-do list gets longer, spending time in the kitchen to prepare a nutritious, flavorful meal for you and your family can seem almost impossible. From buying gifts and entertaining guests to coordinating travel arrangements, sitting down to well-balanced meals often takes the back burner.

Lars Dreiøe joins Sobi as Senior Vice President, Chief Quality & Compliance Officer
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Lars Dreiøe has been appointed Senior Vice President Chief Quality & Compliance Officer (CQCO). Lars Dreiøe joins Sobi from global pharmaceutical company ALK in Denmark where he has been International Head of Quality.

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients
SAN CARLOS, CA--(Marketwired - December 17, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments

VU University Medical Center Amsterdam and SomaLogic Announce First Continental European Deployment of SOMAscan(R) Proteomics Assay
AMSTERDAM, THE NETHERLANDS, and BOULDER CO--(Marketwired - December 17, 2015) - SomaLogic, Inc., and VU University Medical Center Amsterdam (VUmc), announced today that the SOMAscan® assay, a breakthrough proteomics platform, will be deployed at VUmc for its scientists' use in multiple different biomedical research projects. The assay will be performed under the direction of Dr

MYOS Corporation Announces Strategic Investment by RENS Technology Inc.
MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS)

ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS

NeuroRx Provides Clinical Development Update for Cyclurad(TM), a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder
NeuroRx, a clinical stage pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders, today announced its plans for advancing Cyclurad™, the company's lead drug candidate, into a Phase II/III clinical trial for the treatment of acute suicidal crisis associated with bipolar depression

Global Consumption Growth Drives California Walnut Growers
FRESNO, CA--(Marketwired - December 15, 2015) - Positive walnut consumption growth in emerging countries like Australia, South America, South-East Asia and the European Union will drive global consumption trends in upcoming years. Consumption in more mature markets such as China and the U.S. will continue to grow, albeit at a slightly slower rate

MBio Diagnostics Announces a License and Development Partnership With Roka Bioscience, Inc.
BOULDER, CO--(Marketwired - December 15, 2015) - MBio Diagnostics, Inc., a company leading a new era in rapid, on-the-spot clinical diagnostics and sample testing, today announced a product development partnership and licensing agreement with Roka Bioscience, Inc

Mamma Chia Debuts Reduced-Sugar Organic Chia Vitality Bars
Mamma Chia, the pioneer of the chia revolution, is launching a new line of Organic Chia Vitality Bars with just four grams of sugar! Each lightly-sweetened bar is a tasty anytime snack that delivers the powerful nutrients of chia in a great-tasting quartet of delicious new flavor combinations

Betancourt Nutrition Introduces BCAA Plus With Sustamine(R) L-Alanyl-L-Glutamine
NEW YORK, NY--(Marketwired - December 15, 2015) - Betancourt Nutrition is introducing BCAA Plus with Sustamine® L-Alanyl-L-Glutamine this December. It contains 1,500mg of Sustamine® and Taurine for better water absorption.*

ContraFect Corporation Concludes Phase 1 Study of CF-301
YONKERS, NY--(Marketwired - December 15, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced the Phase 1, first-in-human study of CF-301 has concluded

Wella Professionals Launched the Elements Range-Inspired by Nature
Business Wire IndiaWella Professionals introduced to the Indian market Elements; the first Wella Professionals range of care products which are free of sulfates, parabens and artificial colorants. To provide the luxurious experience Wella Professionals has specially created a new fragrance, inspired by the green wood’s of the Amazon forest

Hershey India to Supply SOFIT, Soya Milk Nutritional Beverage, to the Victims of the Chennai Floods
Business Wire IndiaHershey India Pvt. Ltd., a wholly owned subsidiary of The Hershey Company, today pledged to supply 4, 00,000, 200ml packs of SOFIT for the residents of Chennai who have been uprooted in the recent floods. Hershey India has tied up with United Way Mumbai to distribute SOFIT to smaller NGOs working in the worst affected places in Chennai

Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Business Wire India

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Business Wire IndiaSanofi and Boehringer Ingelheim today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi animal health business (“Merial”) with an enterprise value of €11

`Moo-ve Over Alternatives, Milk Packs a Nutrient Punch
(Family Features) Soy, rice, and almond milk. Are these non-dairy milks giving you the nutrients you need? The truth is, not all milk alternatives have the same nutrients as real milk, so it's important to know what you are getting in each glass.

Quincy Bioscience Launches New Prevagen Website
MADISON, WI--(Marketwired - December 30, 2014) - Quincy Bioscience announces the launch of its new Prevagen website. Prevagen is the company's flagship consumer product, a dietary supplement, which works to support healthy brain function and helps improve memory.

EnWave Signs Non-Exclusive License With Merck, Agrees to Build Second Generation Radiant Energy Vacuum Dryer

First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis
Novartis International AG /First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

It's Time for a Better Taco: Del Taco and JENNIE-O(R) Brand Teams Up on Delicious Turkey Items
Del Taco says it's time for a better taco! The chain, with nearly 550 locations nationwide, has announced it has teamed up with the JENNIE-O® brand to develop turkey in developing a lean, seasoned ground turkey recipe using a proprietary blend of spices

Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications
Cytokinetics Expects to Receive Over $75 Million in Committed Capital and Reimbursements For Planned Activities  

Snacking Done Right
(Family Features) What makes a healthy and satisfying snack for children? A well-balanced snack with good nutrition can help kids grow and provide them with the proper support and energy needed for school, sports and other daily activities

Stevia Corp. Confirms Protocol to Produce Synthetic CBD
Stevia Corp

Prima BioMed Announces Immutep's IMP321 Patent Application Receives Canadian Patent Office Notice of Grant
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company") is pleased to announce that it has received a Notice of Grant from the Canadian Patent Office for Patent application CA 2,732,570 entitled "Use of MHC class II Ligands as Adjuvants for Vaccination and of LAG-3 in Cancer Treatment." This patent is licensed from the Institute Gustave Roussy and Merck Serono SA.

Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted

ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that the U.S

Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc

Publication of the Agenda for the Nutreco Extraordinary General Meeting
Nutreco N.V. invites its shareholders for the forthcoming Extraordinary General Meeting to be held on Monday, 9 February 2015 at 14.30 CET at the Flint, Coninckstraat 60 in Amersfoort, The Netherlands.

Sobi's 2011 Long-Term incentive Programme meets all objectives
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2011 Long-Term Incentive programme met its objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2011 programme is 514 808.

Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
Mechelen, Belgium; 19 December 2014 - Galapagos NV (Euronext: GLPG) announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (e.g., G551D)

Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million
FREISING, GERMANY--(Marketwired - December 18, 2014) - Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a share exchange transaction with Pieris AG, a German stock corporation pursuant to which Pieris AG became a wholly-owned subsidiary of the Company

UPDATE - 'Let It Move You(TM)' From the Inside Out: Zumba Provides Simple Tips to Tap Into Your Inner Happy Place for the New Year
MIAMI, FL--(Marketwired - December 18, 2014) - Every year, millions of Americans commit to challenging New Year's resolutions, but research has shown only 8 percent actually stick to them.1 While it may be grueling to reach ambitious goals of weight loss or exercise, starting from within and achieving happiness may be the key to long-term success

'Let It Move You' From the Inside Out: Zumba Provides Simple Tips to Tap Into Your Inner Happy Place for the New Year
MIAMI, FL--(Marketwired - December 18, 2014) - Every year, millions of Americans commit to challenging New Year's resolutions, but research has shown only 8 percent actually stick to them. While it may be grueling to set ambitious goals of weight loss or exercise, starting from within and achieving happiness may be the key to long-term success

Quincy Bioscience Kicks Off the 2015 Better Memory Tour
MADISON, WI--(Marketwired - December 17, 2014) - Quincy Bioscience announces the start of the 2015 Better Memory Tour. The Prevagen Express will travel to various health food centers and health expos across the country to educate the public on the importance of taking proactive steps toward better brain health.

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that its Phase 1/2 Study of HS-410 in bladder cancer patients is open for enrollment. HS-410 is a biologic product candidate designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer.

Stellar Biotechnologies, Inc. Announces Meeting and Record Date and Approval of Advance Notice Policy
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it will hold an annual general and special meeting of shareholders (the "Meeting") on February 13, 2014. The record date for the shareholders entitled to vote at the Meeting has been set as shareholders of record as at the close of business on January 9, 2014.

Sobi to temporarily withdraw New Drug Application for Orfadin® oral suspension in the US
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its decision to withdraw the company's New Drug Application for an oral suspension of Orfadin in the US

Quincy Bioscience Announces the Kickoff of the Prevagen Blog
MADISON, WI--(Marketwired - December 23, 2013) - Quincy Bioscience, best known as the creators of leading memory supplement Prevagen®, gives more resources and opportunities for consumers to learn tips for better brain health this holiday season. The Wisconsin-based biotech company is thrilled to present the takeoff of the new Prevagen Blog.

RayBiotech, Inc. Announces Recipients of 2013 Innovative Research Grants
RayBiotech, Inc. today announced the recipients of its 2013 Innovative Research Grants. The 2013 RayBiotech Innovative Research Grant Program is targeted to a broad range of basic and applied research topics in the life sciences

Recap of NanoViricides, Inc. CEO Dr. Eugene Seymour Clear Channel Business Talk Radio Interview
NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company today announced that Michael Yorba of Clear Channel's Business Talk Radio Show, The Traders Network, interviewed CEO Dr. Eugene Seymour live on December 19, 2013.

MetaStat, Inc. Announces Issuance of U.S. Patent for Its MenaCalc(TM) Platform
MetaStat, Inc

Tree Nut Consumption Associated With Reduced Total and Cause-Specific Mortality
FRESNO, CA--(Marketwired - December 19, 2013) - In a study published November 20, 2013 in the New England Journal of Medicine[1], researchers looked at the association of nut consumption with total and cause-specific mortality among 76,464 women in the Nurses' Health Study and 42,498 men in the Health Professionals Follow-up Study

Sobi to take direct responsibility for Orfadin in the US, Canada and Latin America
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has decided to take direct responsibility for Orfadin® in the US, Canada, and Latin America by terminating the current distributorship agreement with their partner Rare Disease Therapeutics, Inc (RDT). Financial details were not disclosed.

NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute(TM) Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer

ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc

Sobi moves to Large Cap
NASDAQ OMX today announced that Swedish Orphan Biovitrum AB (publ) (Sobi) will, as per 2 January 2014, move to the Large Cap listing on the NASDAQ OMX Stockholm Stock Exchange.

Almas Jiwani, President of UN Women National Committee Canada, to Address Panel on Women and Youth in Agriculture at AGCO Africa Summit in Berlin
Almas Jiwani, President of United Nations Women National Committee Canada, will address a panel on Women and Youth in Agriculture at the Third Annual AGCO Africa Summit in Berlin on Jan. 20, 2014.

RayBiotech, Inc. Announces Partnership With Fox Chase Cancer Center
RayBiotech, Inc. ("RBI") today announced that it has entered into a partnership with the Genomics Core Facility of Fox Chase Cancer Center. Under the terms of the partnership, RayBiotech will provide comprehensive GLP-compliant biomarker discovery and validation services to Fox Chase Cancer Center and its researchers

NYC Plastic Surgeon Uses Botox to Treat Migraines
Plastic Surgeon, Dr. Yael Halaas, offers injectables to her patients in the New York City area. For adults with chronic migraines (15 or more headache days a month) Dr. Halaas offers her patients BOTOX injections.

Radius Names Robert Ward President and Chief Executive Officer
Radius Health, Inc. ("Radius") announced today the appointment of Robert Ward as President and Chief Executive Officer. Mr

Global Clean Energy, Inc. Updates Finger Lakes, New York Waste to Fuels Development
Global Clean Energy, Inc. (OTC PINK: GCEI) is proceeding with Full Circle Renewables,LLC to develop an Anaerobic Digestion AD development on the Seneca AgBio Energy Park in Romulus, New York. GCE and Seneca will provide land, infrastructure, rail access and gas input facility while Full Circle will provide the technology and operations.

MetaStat Announces Poster Presentation at the 2013 San Antonio Breast Cancer Symposium
MetaStat, Inc

Tree Nut Consumption Associated with Reduced Total and Cause-Specific Mortality
In a study published November 20, 2013 in the New England Journal of Medicine1, researchers looked at the association of nut consumption with total and cause-specific mortality among 76,464 women in the Nurses’ Health Study and 42,498 men in the Health Professionals Follow-up Study

Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis (RMS)

Hydroxycut Offers Tips for Avoiding Holiday Weight Gain
During the year, families often gather to celebrate multiple holidays. Thanksgiving, Christmas, Hanukkah, and New Year's Eve are several of the occasions on which families share large meals and indulge in their favorite comfort foods

All American Pet Company, Inc.'s New Super-Premium 27% Protein Power NutraBar(TM) Was Seen by Millions During Its Weekend TV Debut on CNN International and the Headline Network
All American Pet Company, Inc. (OTCQB: AAPT) -- Presented by well-known pet advocate, Wendy Diamond, All American Pet Brand's NutraBars made multiple appearances on CNN International which reaches more than 200 million households in over 200 countries and its sister network, HLN, which focuses on national "must-see, must-share" stories of the day. During the on-air segments, http://youtu

Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today provides commentary on a front page New York Times article published December 23, 2012 titled, "Genetic Gamble; New Approaches to Fighting Cancer."

Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea
Actelion Pharmaceuticals Ltd /Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Addex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor
Addex Therapeutics /Addex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Market for Kinase Inhibitors Heats Up: Kalorama
The cancer kinase inhibitor market is estimated at $12.1 billion worldwide for 2012, representing annual revenue growth of 16.9% over 2007. The effectiveness of kinase inhibitors has sparked interest from major pharmaceutical companies, according to the healthcare market research publisher, Kalorama Information

DSM completes acquisition of Fortitech and strengthens its human nutrition business
Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has completed the acquisition of Fortitech, Inc. (Fortitech). The transaction, for a total enterprise value of USD 634 million (about €495 million) strengthens DSM's Human Nutrition and Health business, by expanding the company's value chain presence and adding additional capabilities

Dr. Reddy's announces it has acquired 37,460 shares (0.1%) of OctoPlus N.V. on 18 December 2012
This is a press release by Reddy Netherlands B.V. (the "Offeror"), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's"), and Dr

Near Term Catalyst Has ArQule Poised for a Move Up
ArQule, Inc. engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.

ArQule (ARQL) Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow

GeoVax Announces Full Enrollment of Phase 1 Clinical Trial for 2nd Generation HIV/AIDS Vaccine
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, is pleased to announce full enrollment in a 48 patient Phase 1 trial testing the safety and immunogenicity of its 2nd generation adjuvanted DNA/MVA vaccine for the prevention of HIV infection

Relay Technology Management Announces Pipeline-by-Pathway Target Searching to Enable Biologically-Based Business Intelligence for the Pharmaceutical Industry
Relay Technology Management Inc. is pleased to announce the release of the pipeline-by-pathway target searching module as part of version 1.2 of Business Development Live!, Relay's flagship real-time comparative asset analysis and trend analytics software-as-a-service for the life sciences industry

A Strong Speculative BioPharma Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow

Actelion's ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod to proceed to Phase III clinical development in psoriasis
Actelion Pharmaceuticals Ltd /Actelion's ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod to proceed to Phase III clinical development in psoriasis . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Dr. Reddy's announces it has acquired 182,588 shares (0.3%) of OctoPlus N.V. on 17 December 2012
This is a press release by Reddy Netherlands B.V. (the "Offeror"), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's"), and Dr

How to Love Your Heart
(Family Features) It beats about 100,000 times a day, 35 million times a year. It pumps blood through the body three times every minute, taking that blood on the equivalent of a 12,000 mile trek every 24 hours. Even at rest, it works twice as hard as the leg muscles of a person running. The heart is a remarkable, vital muscle that warrants great care and maintenance

GCS-100 Demonstrates Statistically Significant Reduction in Liver Fibrosis
La Jolla Pharmaceutical Company (OTCQB: LJPC) (the "Company" and "La Jolla"), a leader in the development of therapeutics that target galectin-3, announced today the results of a mouse study examining the effect of GCS-100 on liver fibrosis

RiceBran Technologies and Prozyn BioSolutions Announce Distribution Agreement for South America

Bio-Rad Signs Definitive Agreement to Acquire AbD Serotec
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced that it has signed a definitive agreement to acquire AbD Serotec, a division of MorphoSys AG for 53 million euros in cash

AGCO Starts Local Production in North Africa
AGCO, Your Agriculture Company (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment, held a ceremony yesterday to mark the production of the first Massey Ferguson tractor produced by AGCO’s joint venture in Constantine, Algeria

AspenBio Closes $1.6 Million Registered Direct Offering
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging in vitro diagnostic company, has closed its previously announced registered direct offering for the sale of 1,605,000 shares of its no par value common stock ("Common Stock") at a price of $1.02 per share, generating proceeds of $1.6 million before commissions and expenses

National Consumer Research Institute Predicts Top Five Health Trends for 2012
The need for better sleep and a growing appetite for liquid energy shots and health-related smartphone apps are among the top consumer health trends expected to make headlines in 2012, according to a leading national research group studying health-related attitudes and behavior in America.

AspenBio Announces Registered Direct Offering of Approximately $1.6 Million
AspenBio Pharma, Inc

Promising new drug targets against kidney cancer identified
Scientists have laid the foundation of completely understanding the intricacies of distinct kidney cancer subtypes, which could lead to better treatments for the disease.

Brain cell malfunction linked to schizophrenia
Defect in certain portions of protein that package DNA is the root cause of Schizophrenia and the deficit is especially pronounced in younger people, a new study has suggested.

Mutation in gene critical for human development causes lethal arrhythmia
Altered function of a gene that is critical for human development interferes with the growth of the cardiac conduction system (CCS) and causes lethal arrhythmias, a new study has claimed.

Cancer drugs may also combat antibiotic resistance
Drugs used for cancer treatment may also help in combating antibiotic resistance, a new study has revealed.

Genes that increase risk of thyroid cancer identified
Scientists have discovered the genetic cause of thyroid cancer, which can lead to the formulation of more targeted treatment for the disease.

Tiny silk microneedles to deliver drugs without pain
Scientists have developed a new silk-based microneedle system able to deliver precise amounts of drugs over time and without need for refrigeration.

Protein shakes 'partly to blame for baldness'
Protein shakes are partly responsible for increase in baldness as they lead to the production of certain chemicals in the body, which causes or worsens hair loss, a new study has revealed.

Comment on this story

Share